Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 31, 2023
Finance
Oct. 30 Quick Takes: VCs pile in for MapLight’s $225M series C
Plus: Deciphera gets lift from TGCT readout and updates from Hengrui, Merck KGaA, AnHeart, Nippon Kayaku, Novartis, GSK and more
BioCentury | Oct 27, 2023
Discovery & Translation
BMS’s dual lipid kinase inhibitor; plus prime editing in NHPs and more
BioCentury’s roundup of translational innovation
BioCentury | Aug 1, 2023
Deals
Pharma deals seek novelty with heavy focus on first in class
An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
BioCentury | Jun 1, 2023
Deals
June 1 Quick Takes: Lonza expands ADC offering with Synaffix takeout
Plus: Owkin investing $50M to build cancer spatial omics consortium and updates from Pfizer, AbbVie, Eikon, Lexicon, Hookipa, AstraZeneca, CMS and more
BioCentury | May 12, 2023
Product Development
Companies aiming for PARP-1 selectivity
A second generation of PARP inhibitors focused on PARP-1 selectivity starts to make progress
BioCentury | May 10, 2023
Deals
May 9 Quick Takes: Roche taps Zion for brain-penetrating HER2 program
Plus: Gilead acquires XinThera, Amgen partners with TScan and updates from Ascend, Novavax, Gilead and more
BioCentury | Apr 11, 2023
Finance
April 11 Quick Takes: VintaBio debuts with $64M to tackle viral vector bottleneck
Plus: Moderna forecasts up to $15B in 2027 sales of respiratory franchise and updates from HI-Bio, Chinook, Impact-Junshi and more
BioCentury | Dec 22, 2022
Regulation
Dec. 21 Quick Takes: Cash for NASH as Madrigal and Terns raise funds
Plus: FDA, EMA reviewing Pfizer’s etrasimod for ulcerative colitis and updates from ADC, AZ, CytoDyn, NGM-Merck and more
BioCentury | Sep 21, 2022
Deals
Sept. 21 Quick Takes: Germany’s Merck in deal with Nerviano for PARP1 inhibitor
Plus Celltrion gains rights to T cell engager from Abpro, and updates from Moat, Day One, Secura and more
Items per page:
1 - 10 of 143